Andrew J. Schwab

Andrew J. Schwab has an estimated net worth of $456 Million. This is based on reported shares across multiple companies, which include Crinetics Pharmaceuticals, Inc., Entrada Therapeutics, Inc., IDEAYA Biosciences, Inc., Rallybio Corp, ARVINAS, INC., IMPEL NEUROPHARMA INC, Cidara Therapeutics, Inc., VIVEVE MEDICAL, INC., scPharmaceuticals Inc., Cabaletta Bio, Inc., Akouos, Inc., Homology Medicines, Inc., Audentes Therapeutics, Inc., Pear Therapeutics, Inc., PHASERX, INC., Aprea Therapeutics, Inc., Enliven Therapeutics, Inc., Skye Bioscience, Inc., , Flexion Therapeutics Inc, Vor Biopharma Inc., 5:01 Acquisition Corp., EPIRUS Biopharmaceuticals, Inc., Artiva Biotherapeutics, Inc., and Camp4 Therapeutics Corp.

2019 was Andrew J. Schwab's most active year for acquiring shares with 28 total transactions. Andrew J. Schwab's most active month to acquire stocks was the month of January. 2022 was Andrew J. Schwab's most active year for disposing of shares, totalling 56 transactions. Andrew J. Schwab's most active month to dispose stocks was the month of October. 2022 saw Andrew J. Schwab paying a total of $25,520,000.00 for 4,937,646 shares, this is the most they've acquired in one year. In 2019 Andrew J. Schwab cashed out on 13,292,745 shares for a total of $54,804,484.83, their largest year based on trade value.